Substituted indazole derivatives active as kinase inhibitors

Patent metadata

Field	Value
Publication number	US-9255087-B2
Application number	US-201414534617-A
Country	US
Kind code	B2
Filing date	Nov 6, 2014
Priority date	Jul 20, 2007
Publication date	Feb 9, 2016
Grant date	Feb 9, 2016

Abstract

Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.

First claim

What is claimed is:

1. A method for treating a disease selected from breast cancer, lung cancer, non-small cell lung cancer, colorectal cancer, prostate cancer, ovarian cancer, endometrial cancer, gastric cancer, clear cell renal cell carcinoma, uveal melanoma, multiple myeloma, rhabdomyosarcoma, Ewing's sarcoma, Kaposi's sarcoma, medulloblastoma, anaplastic large cell lymphoma, neuroblastoma, rhabdomyosarcoma, glioblastoma, inflammatory myofibroblastic tumor, melanomas, Ewing's sarcomas, retinoblastomas, squamous cell carcinoma, seminoma, teratocarcinoma, xeroderma pigmentosum, and thyroid follicular cancer, said method comprising administering to a patient in need thereof an amount of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, or a pharmaceutically acceptable salt thereof, effective to treat said disease.

2. A method according to claim 1 , wherein said disease is selected from breast cancer, non-small cell lung cancer, colorectal cancer, prostate cancer, melanoma, neuroblastoma, and glioblastoma.

3. A method according to claim 1 , wherein said disease is selected from non-small cell lung cancer, colorectal cancer, neuroblastoma, and glioblastoma.

4. A method according to claim 1 , wherein said disease is non-small cell lung cancer.

5. A method according to claim 1 , wherein said disease is colorectal cancer.

6. A method according to claim 1 , wherein said disease is neuroblastoma.

7. A method according to claim 1 , wherein said disease is glioblastoma.

8. A method for treating a patient having cancer, wherein tumors from said patient are anaplastic lymphoma kinase positive, said method comprising administering to said patient an amount of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, or a pharmaceutically acceptable salt thereof, that is effective to treat said cancer.

9. A method according to claim 8 , wherein said cancer is selected from breast cancer, non-small cell lung cancer, colorectal cancer, prostate cancer, melanoma, neuroblastoma, and glioblastoma.

10. A method according to claim 8 , wherein said cancer is selected from non-small cell lung cancer, colorectal cancer, neuroblastoma, and glioblastoma.

11. A method according to claim 8 , wherein said cancer is non-small cell lung cancer.

12. A method according to claim 8 , wherein said cancer is colorectal cancer.

13. A method according to claim 8 , wherein said cancer is neuroblastoma.

14. A method according to claim 8 , wherein said cancer is glioblastoma.

15. A method of inhibiting anaplastic lymphoma kinase activity, comprising contacting anaplastic lymphoma kinase with an effective amount of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, or a pharmaceutically acceptable salt thereof.

Assignees

• Nerviano Medical Sciences Srl

Inventors

• Lombardi Borgia Andrea
• Menichincheri Maria
• Orsini Paolo
• Panzeri Achille
• Perrone Ettore
• Vanotti Ermes
• Nesi Marcella
• Marchionni Chiara

Classifications

• A61P39/06

  Free radical scavengers or antioxidants · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title